Your search returned over 250 studies. The top 250 studies are being displayed. Please use additional keywords or decrease the search distance. Get alerts for new studies
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Bloomington, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Bloomington%, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Eureka, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Eureka, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Normal, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Normal, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Normal, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Ottawa, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Ottawa, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Pekin, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Peoria, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Peoria, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Peoria, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Peru, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Peru, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Princeton, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Princeton, Illinois
- Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms
Location: Spring Valley, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Bloomington, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Eureka, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Normal, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Normal, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Ottawa, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Peoria, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Peoria, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Peoria, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Peru, Illinois
- PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Conditions: Cutaneous Melanoma
Location: Princeton, Illinois
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leuke
Conditions: Leukemia
Location: Joliet, Illinois
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma
Location: Joliet, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Bloomington%, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Eureka, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Eureka, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Normal, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Normal, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Normal, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Ottawa, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Ottawa, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Pekin, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Peoria, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Peoria, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Peoria, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Peru, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Peru, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Princeton, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Princeton, Illinois
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
Location: Spring Valley, Illinois
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: Leukemia
Location: Joliet, Illinois
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Joliet, Illinois
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Location: Joliet, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Bloomington%, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Eureka, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Eureka, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Joliet, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Normal, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Normal, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Normal, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Ottawa, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Ottawa, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Pekin, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Peoria, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Peoria, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Peoria, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Peru, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Peru, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Princeton, Illinois
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Leukemia - Myelodysplastic Syndromes
Location: Spring Valley, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Bloomington, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Bloomington%, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Pekin, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peru, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peru, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Princeton, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Princeton, Illinois
- Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Spring Valley, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Bloomington, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Eureka, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Joliet, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Normal, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Normal, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Ottawa, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Ottawa, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Peoria, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Peoria, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Peoria, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Peru, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Princeton, Illinois
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Esophageal Cancer
Location: Spring Valley, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Bloomington, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Bloomington%, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Eureka, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Normal, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Ottawa, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Pekin, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peoria, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peru, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Peru, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Princeton, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Princeton, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Spring Valley, Illinois
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Location: Spring Valley, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Bloomington, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Bloomington%, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Eureka, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Eureka, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Normal, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Normal, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Normal, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Ottawa, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Pekin, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Peoria, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Peoria, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Peoria, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Peru, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Peru, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Princeton, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Princeton, Illinois
- Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Location: Spring Valley, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Bloomington%, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Eureka, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Eureka, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Normal, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Normal, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Normal, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Ottawa, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Ottawa, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Pekin, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Peoria, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Peoria, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Peoria, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Peru, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Peru, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Princeton, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Princeton, Illinois
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: Leukemia
Location: Spring Valley, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Bloomington%, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Pekin, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peoria, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peoria, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peoria, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peru, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peru, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Princeton, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Princeton, Illinois
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Spring Valley, Illinois
- IMC-A12 and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Conditions: Adult Malignant Fibrous Histiocytoma of Bone - Sarcoma
Location: Joliet, Illinois
- IMC-A12 and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Conditions: Adult Malignant Fibrous Histiocytoma of Bone - Sarcoma
Location: Peoria, Illinois
- Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
Conditions: Melanoma
Location: Peoria, Illinois
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Conditions: Prostate Cancer
Location: Joliet, Illinois
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Tri
Conditions: Breast Cancer
Location: Normal, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Bloomington, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Bloomington%, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Eureka, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Eureka, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Joliet, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Normal, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Normal, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Normal, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Normal, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Pekin, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Peoria, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Peoria, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Peoria, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Peru, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Peru, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Princeton, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Princeton, Illinois
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Location: Spring Valley, Illinois
- E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Conditions: Bladder Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Joliet, Illinois
- E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Conditions: Bladder Cancer - Transitional Cell Cancer of the Renal Pelvis and Ureter - Urethral Cancer
Location: Peoria, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Bloomington, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Bloomington%, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Eureka, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Eureka, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Normal, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Normal, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Normal, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Ottawa, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Pekin, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peoria, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peoria, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peoria, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peru, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Peru, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Princeton, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Princeton, Illinois
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Location: Spring Valley, Illinois
- A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis
Conditions: Atopic Dermatitis
Location: Peru, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Bloomington, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Bloomington%, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Eureka, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Eureka, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Normal, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Normal, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Normal, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Ottawa, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Ottawa, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Pekin, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Peoria, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Peoria, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Peoria, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Peru, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Peru, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Princeton, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Princeton, Illinois
- Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Conditions: Neuroendocrine Carcinoma
Location: Spring Valley, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Bloomington%, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Eureka, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Normal, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Ottawa, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Pekin, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peoria, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peoria, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peoria, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peru, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Peru, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Princeton, Illinois
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Location: Princeton, Illinois
|